NeuBase Therapeutics, Inc.: Nasdaq/NYSE listing notice — NeuBase receives Nasdaq deficiency notice; bid price below $1.00 for 30 days

NeuBase Therapeutics, Inc.

Nasdaq notified NeuBase on Nov 3, 2023 that its common stock bid price has been below $1.00 for 30 consecutive business days.
Company has 180 days, until May 1, 2024, to regain compliance by closing at $1.00 or higher for at least 10 consecutive business days.
If not cured by May 1, NeuBase may qualify for a second 180-day period by meeting other listing standards and providing a reverse split plan.
The notice does not immediately affect trading on Nasdaq; stock continues to trade under symbol NBSE.
Company intends to monitor bid price and consider options to regain compliance, but no assurance of success.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NeuBase Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

ule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”),

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-114809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.